Soleno Therapeutics Stock Forecast, Price & News

Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

Is Soleno Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Soleno Therapeutics stock.
View analyst ratings for Soleno Therapeutics or view top-rated stocks.

How has Soleno Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SLNO stock has decreased by 83.3% and is now trading at $0.42.
View which stocks have been most impacted by COVID-19.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 721,000 shares, an increase of 18.3% from the December 15th total of 609,500 shares. Based on an average trading volume of 256,700 shares, the days-to-cover ratio is currently 2.8 days. Currently, 1.3% of the shares of the company are short sold.
View Soleno Therapeutics' Short Interest.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Soleno Therapeutics.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.01.
View Soleno Therapeutics' earnings history.

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics's stock reverse split before market open on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for SLNO?

1 brokers have issued 12-month price objectives for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Soleno Therapeutics' stock price to reach $8.00 in the next year. This suggests a possible upside of 1,804.8% from the stock's current price.
View analysts' price targets for Soleno Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:

• Anish Bhatnagar, President, Chief Executive Officer & Director
• James H. Mackaness, Chief Financial Officer (LinkedIn Profile)
• Kristen Yen, Vice President-Clinical Operations
• Harish Ravivarapu, Vice President-Technical Operations
• Patricia C. Hirano, Head-Regulatory Affairs & Quality

Who are some of Soleno Therapeutics' key competitors?

Some companies that are related to Soleno Therapeutics include Movano (MOVE), Electromed (ELMD), FONAR (FONR), IRIDEX (IRIX), BioSig Technologies (BSGM), Second Sight Medical Products (EYES), electroCore (ECOR), Yubo International Biotech (YBGJ), Fc Global Realty (FCRE), Precision Optics (PEYE), Positron (POSC), ENDRA Life Sciences (NDRA), Tivic Health Systems (TIVC), Vaso (VASO) and Helius Medical Technologies (HSDT).
View all of SLNO's competitors.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $0.42.

How much money does Soleno Therapeutics make?

Soleno Therapeutics has a market capitalization of $33.52 million. The company earns $-24.64 million in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Soleno Therapeutics have?

Soleno Therapeutics employs 17 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

Where are Soleno Therapeutics' headquarters?

Soleno Therapeutics is headquartered at 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 213-8444, via email at [email protected], or via fax at 650-213-8383.